Hypoparathyroidism
ICD-10 E20.0 · ICD-11 5A50.0

Hypoparathyroidism: What to Do When Conventional Activated Vitamin D Therapy Has Not Achieved Target Calcium Control

Clinical Scenario

This protocol is for patients with hypoparathyroidism in whom the standard first-line approach has not adequately controlled calcium levels. When conventional management fails to meet its treatment targets, a structured next-step approach is required.

Why the Previous Treatment Was Insufficient

Conventional treatment — activated vitamin D analogues (alfacalcidol or calcitriol) together with dietary calcium, calcium supplementation, and vitamin D supplementation — did not achieve the required targets: calcium within the target range, freedom from symptomatic hypocalcaemia, phosphate and magnesium within the reference range, normal 24-hour urinary calcium excretion, and an adequate 25-hydroxyvitamin D level. Failure to reach these goals is the trigger for escalation.

Next Treatment Step (Partial Overview)

The approach at this stage centres on PTH replacement therapy delivered via a once-daily subcutaneous route, with dose individually titrated according to calcium response. The complete selection, titration algorithm, and management of concurrent medications are detailed in the full protocol.

Treatment Goals

Sustained calcium levels in the target range without ongoing reliance on activated vitamin D or calcium supplements; normalisation of phosphate levels; reduced 24-hour urinary calcium excretion; improved eGFR. Treatment effects are evaluated 6–12 months after initiation.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/ejendo/lvaf222

Doses of palopegteriparatide are adjusted according to calcium levels with up or down titration once a week (with a maximum change of ±3 μg/day each week).

We suggest to titrate the dose of PTH replacement therapy to achieve sustained calcium levels in the target range without the need for concurrent activated vitamin D treatment or calcium supplements.

If PTH replacement therapy is initiated, we suggest evaluating the treatment effects after 6–12 months, depending on treatment goals.

View source ↗